| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-11-27 | Juno Therapeutics (USA - WA) | vice president | nomination | Cancer - Oncology | Nomination | |
| 2017-11-27 | Brammer Bio (USA - MA) | manufacturing site in Cambridge | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-11-14 | Theradiag (France) Biogen (USA - MA) | LISA TRACKER kits for monitoring Flixabi® (an infliximab biosimilar) | collaboration | Collaboration agreement | ||
| 2017-11-13 | AdAlta (Australia) XL-protein (Germany) | PASylation® technology applied to AD-114 | fibrosis | licensing | Fibrotic diseases | Licensing agreement |
| 2017-11-13 | Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (UK) Curevac (Germany) | Cas9 mRNA constructs | liver diseases | collaboration | Hepatic diseases - Liver diseases | Collaboration agreement |
| 2017-11-13 | Homology Medicines (USA - MA) Novartis (Switzerland) | gene editing technology | R&D - research - development | Technology - Services - Ophtalmological diseases - Hematological diseases | Research agreement | |
| 2017-11-12 | Restructuring | |||||
| 2017-11-10 | Medivir (Sweden) | vice president strategic business development | nomination | Infectious diseases | Nomination | |
| 2017-11-09 | Dynacure (France) Ionis Pharmaceuticals (USA - CA) | IONIS-DNM2-2.5Rx (Dyn101) | centronuclear myopathy (CNM) | licensing | Rare diseases - Genetic diseases | Licensing agreement |
| 2017-11-09 | Avrobio (USA - MA) | nomination | Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases | Nomination | ||
| 2017-11-09 | Sangamo Therapeutics (USA - CA) | head of technical operations and manufacturing | nomination | Rare diseases - Genetic diseases - Technology - Services | Nomination | |
| 2017-11-09 | Sangamo Therapeutics (USA - CA) | cGMP manufacturing facility, new headquarters | construction of new premises | Rare diseases - Genetic diseases - Technology - Services | Construction of new premises | |
| 2017-11-09 | apceth (Germany) | supervisory board | nomination | Technology - Services | Nomination | |
| 2017-11-08 | Boehringer Ingelheim (Germany) Mina Therapeutics (UK) | small activating RNA (“saRNA”) | NASH (non-alcoholic steatohepatitis), fibrotic diseases | licensing - development | Fibrotic diseases - Hepatic diseases - Liver diseases | Licensing agreement |
| 2017-11-06 | VBL Therapeutics (Israel) NanoCarrier (Japan) | VB-111 (ofranergene obadenovec) | development - licensing - commercialisation | Cancer - Oncology | Licensing agreement | |
| 2017-11-06 | Adaptimmune (UK) | U.K. headquarters | opening of new premises | Cancer - Oncology | Opening of new premises | |
| 2017-11-02 | Genentech, a member of Roche group (USA - Switzerland) AC Immune (Switzerland) | anti-Tau antibodies | Alzheimer’s disease and other neurodegenerative disease | R&D - research - development - commercialisation - licensing | Neurodegenerative diseases | Milestone |
| 2017-11-01 | Merck&Co (USA - NJ) Samsung Biologics (South Korea) | biopharmaceutical manufacturing and biologics process development.,biosimilar candidates (SB4 Enbrel (etanercept), SB2 Remicade (infliximab), SB5 Humira (adalimumab), SB3 Herceptin (trastuzumab), MK-1293 Lantus (insulin glargine) | development, commercialisation | Autoimmune diseases - Inflammatory diseases - Rheumatic diseases - Dermatological diseases - Digestive diseases | Development agreement | |
| 2017-10-31 | Basilea Pharmaceutica (Switzerland) | chief medical officer | nomination | Infectious diseases | Nomination | |
| 2017-10-30 | AstraZeneca (UK) Mereo Biopharma (UK) | AZD9668 | alpha-1 antitrypsin deficiency (AATD) | licensing | Rare diseases - Genetic diseases - Respiratory diseases | Licensing agreement |
